Filament Health
PEX010 · Botanical Psilocybin Extract · Opioid Use Disorder
Company Overview
Filament Health is a drug development company working with naturally-derived psychedelic medicines. Their lead program PEX010 is a standardized botanical psilocybin extract. ⚠ FINANCIAL DISTRESS: Filament was delisted from Cboe Canada in May 2025 and now trades on OTC Pink (Limited Information tier). As of Q4 2025, the company had $337,082 in cash. Going concern risk has been disclosed. Active trials are small investigator-initiated feasibility studies (~10 patients each), not conventional Phase 2 trials. Pursuing the FDA's botanical drug development pathway.
Pipeline
| Drug / Compound | Stage | Indication |
|---|---|---|
PEX010 Botanical psilocybin extract (standardized natural extraction) | Phase 2 (Investigator-Initiated) | Opioid Use Disorder |
FH-202 Botanical DMT extract | Preclinical | Depression |
Key Financials
- Cash Position
- $337,082
- Burn Rate
- Under $1M/quarter
- Last Reported
- Q4 2025
Financial data is approximate. Always verify with official SEC filings.
Upcoming Catalysts
- H2 2026PEX010 feasibility study data readout (OUD)Clinical
Recent News
- 2025-05Filament Health delisted from Cboe Canada; shares move to OTC Pink amid going concern disclosure
News items are manually curated from public company press releases.
External Links
Looking for psychedelic therapy?
Browse our directory of 700+ verified ketamine and psychedelic therapy clinics across 49 states. Find providers near you who offer ketamine and psychedelic-assisted therapy.
Disclaimer: This page is for informational purposes only and does not constitute investment, medical, or financial advice. Pipeline status, financial figures, and catalyst dates are approximate and based on publicly available information as of 2026-02-25. Always consult official company filings and a qualified financial advisor before making investment decisions.